News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Oct 25, 2005

  Insmed Receives European Orphan Drug Designation for SomatoKine for the Treatment of Extreme Insulin Resistance; Company to Initiate Clinial Trial in Type A Insulin Resistance
• Oct 25, 2005

  FDA to Review Insmed's Complete Response to Approvable Letter for iPlex
• Oct 24, 2005

  Insmed to Present at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference
• Oct 18, 2005

  Insmed to Present at the BIO Investor Forum Conference
• Oct 17, 2005

  Insmed Submits Response to FDA Approvable Letter for iPlex
• Sep 29, 2005

  Insmed Issues Statement Regarding IPLEX(TM) Approvable Letter Press Release
• Sep 29, 2005

  Insmed Provides Update on iPlex Pivotal Trial Data in Severe Primary IGF-1 Deficiency
• Sep 25, 2005

  Insmed Receives Approvable Letter for iPlex(TM); Conference Call Tomorrow at 8:00am EST
• Sep 24, 2005

  Insmed Announces Appointment of Dr. Kenneth Attie; Former Genentech Researcher Assumes Role as Medical Director
• Sep 19, 2005

  SomatoKine(R) Pivotal Data to Be Featured in a Podium Presentation at the ESPE/LWPES 7th Joint Meeting of Pediatric Endocriniology in Lyon, France
• Aug 8, 2005

  Insmed Incorporated Reports Financial Results for the Second Quarter and First Half of 2005
• Aug 2, 2005

  Insmed to Release Second Quarter Financial Results; Monday, August 8
• Jun 10, 2005

  FDA Extends PDUFA Date for SomatoKine to October 03, 2005
• May 31, 2005

  Insmed Reports Detailed Positive Results from Its Pivotal Clinical Trial of SomatoKine in Patients with Growth Hormone Insensitivity Syndrome
• May 25, 2005

  Insmed to Present at Needham & Company Biotechnology Conference May 26, 2005
• May 24, 2005

  Insmed Announces the Continuation of Litigation in the United Kingdom; Judge's Ruling Allows for the Continuation of Legal Action in Suit Filed by Tercica
• May 19, 2005

  Insmed to Present at UBS Global Pharmaceutical Conference May 23, 2005
• May 17, 2005

  Insmed Announces Exclusive Option Agreement with UCSF for Series of IGF-1 Receptor Antagonists; Agreement Expands Collaboration on IGF-1 Program in Prostate Cancer
• May 10, 2005

  Insmed Incorporated Reports Financial Results for First Quarter of 2005
• May 5, 2005

  Insmed Inc. to Webcast First Quarter Earnings Conference Call Thursday, May 12 at 8:30 a.m. (ET)
• Apr 26, 2005

  Insmed Initiates Phase II Trial With SomatoKine(R) in Type A Extreme Insulin Resistance
• Apr 20, 2005

  Insmed Initiates Phase II HIV-Associated Lipodystrophy Trial With Somatokine(R)
• Apr 18, 2005

  Patent Infringement Suit Against Insmed Dismissed
• Apr 13, 2005

  FDA Grants Priority Review for Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
• Mar 16, 2005

  Insmed Incorporated Reports Financial Results for Fourth Quarter and Twelve-Months of 2004
• Mar 15, 2005

  Insmed to Release Fourth Quarter and Year End Financial Results; Wednesday, March 16
• Mar 15, 2005

  Insmed Announces Completion of $35 Million Financing
• Mar 10, 2005

  FDA Accepts for Review Insmed's NDA for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
• Feb 22, 2005

  Insmed Provides Response to United States Patent Lawsuit; Seeks Immediate Dismissal or Summary Judgment for All Claims
• Feb 16, 2005

  Insmed Provides Response to UK Patent Lawsuit
• Jan 7, 2005

  University of Rochester Awarded $6.5 Million to Study Efficacy OF rhIGF-I/rhIGFBP-3, SomatoKine, in the Treatment of Myotonic Dystrophy
• Jan 3, 2005

  Insmed Submits New Drug Application -NDA- to Seek Regulatory Approval of SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome
• Dec 31, 2004

  Insmed Completes New Drug Application -NDA- for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome; Conference Call Scheduled for 11:00 am January 5, 2005
• Dec 30, 2004

  Insmed Incorporated Released the Following Statement in Response to Recent Actions by Tercica, Inc.
• Dec 21, 2004

  Insmed Incorporated Released the Following Statement in Response to a Press Release Made Yesterday by Tercica, Inc.
• Nov 9, 2004

  Insmed Announces Expansion of Patent Portfolio in the Treatment of Diabetes; New European Patent Granted for SomatoKine
• Nov 8, 2004

  Insmed Raises Approximately $8.7 Million in Direct Placement of Common Stock
• Nov 8, 2004

  Insmed Incorporated Reports Financial Results for Third Quarter and First Nine-Months of 2004
• Oct 26, 2004

  Insmed to Present at Rodman and Renshaw Healthcare Conference October 28, 2004; Presentation to Be Webcast Live
• Oct 21, 2004

  Insmed and Tzamal Pharma Announce Agreement for the Promotion and Distribution of SomatoKine in Middle Eastern Territories
• Oct 19, 2004

  Insmed Announces Initiation of Clinical Study of Small Molecule IGF-IR Tyrosine Kinase Inhibitor
• Sep 13, 2004

  Insmed Reports Results from Nine Months of SomatoKine Therapy for a Patient with Extreme Insulin Resistance at the 43rd Meeting of the European Society of Pediatric Endocrinology
• Sep 8, 2004

  Insmed Initiates Phase I Clinical Study for Novel Anti-Tumor Protein
• Aug 17, 2004

  Insmed Requests Halt of Trading of Its Common Stock on the Berlin-Bremen Stock Exchange; Company Also Initiates Short Selling Audit
• Jul 28, 2004

  Insmed Incorporated Reports Financial Results for Second Quarter and First Half of 2004
• Jul 21, 2004

  Insmed to Report Second Quarter Financial Results;Wednesday, July 28
• Jul 20, 2004

  Insmed Reports Update on Pivotal Clinical Trial with SomatoKine: Statistically Significant Increase in Growth Rate Observed at Six Months
• Jul 19, 2004

  Insmed Receives Authorization for Reimbursement for SomatoKine Named Patient Program from France and Italy; Newly Appointed Chief Business Officer Expands the Named Patient Program
• Jul 19, 2004

  Insmed Announces Two Independent Presentations at the National Cancer Institutes 12th Annual Meeting of SPORE
• May 13, 2004

  Breast Cancer Center of Excellence Awarded $10 Million Department of Defense Grant; rhIGFBP-3 Selected as a Candidate Agent in Clinical Trials

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download